Endoxifen is under clinical development by Atossa Therapeutics and currently in Phase II for Ductal Carcinoma In Situ. According to GlobalData, Phase II drugs for Ductal Carcinoma In Situ have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Endoxifen’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Endoxifen overview
Endoxifen is under development for the treatment of HER2 negative breast cancer, mammographic breast density for women and breast cancer for men, recurrent ovarian cancer, triple-negative breast cancer (TNBC), ductal carcinoma in situ. It is administered through oral and topical route. The drug candidate is an active metabolite of tamoxifen. It acts by targeting estrogen receptor and selective PKC (protein kinase C) beta.
It was also under development for gynecomastia.
Atossa Therapeutics overview
Atossa Therapeutics (Atossa), formerly Atossa Genetics, is a clinical-stage biopharmaceutical company. It develops proprietary therapeutics and delivery methods for breast cancer and other breast conditions. The company’s pipeline pharmaceutical programs include endoxifen, an active metabolite of tamoxifen, used for the treatment of breast density and other breast health conditions. Atossa develops patented microcatheter technology to deliver fulvestrant as a potential treatment of ductal carcinoma through the nipple to site of early breast cancer. The company uses its proprietary intraductal microcatheter technology to deliver CAR-T cells into the ducts of the breast for the treatment of breast cancer. The company operates presence in Australia, the US and the UK. Atossa is headquartered in Seattle, Washington, the US.
For a complete picture of Endoxifen’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
